205 related articles for article (PubMed ID: 15533762)
1. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling.
Alaoui-Jamali MA; Dupré I; Qiang H
Drug Resist Updat; 2004; 7(4-5):245-55. PubMed ID: 15533762
[TBL] [Abstract][Full Text] [Related]
2. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
3. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
4. An integrative genomic and proteomic approach to chemosensitivity prediction.
Ma Y; Ding Z; Qian Y; Wan YW; Tosun K; Shi X; Castranova V; Harner EJ; Guo NL
Int J Oncol; 2009 Jan; 34(1):107-15. PubMed ID: 19082483
[TBL] [Abstract][Full Text] [Related]
5. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
6. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer.
Li XH; Li C; Xiao ZQ
J Proteomics; 2011 Nov; 74(12):2642-9. PubMed ID: 21964283
[TBL] [Abstract][Full Text] [Related]
7. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
8. Status of Immune Oncology: Challenges and Opportunities.
Cesano A; Marincola FM; Thurin M
Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
[TBL] [Abstract][Full Text] [Related]
9. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
Smith L; Lind MJ; Welham KJ; Cawkwell L;
Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
[TBL] [Abstract][Full Text] [Related]
10. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
Lin F; Li Z; Hua Y; Lim YP
Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
Jimenez CR; Verheul HM
Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
[TBL] [Abstract][Full Text] [Related]
13. Investigation of cancer drug resistance mechanisms by phosphoproteomics.
Boulos JC; Yousof Idres MR; Efferth T
Pharmacol Res; 2020 Oct; 160():105091. PubMed ID: 32712320
[TBL] [Abstract][Full Text] [Related]
14. A community effort to assess and improve drug sensitivity prediction algorithms.
Costello JC; Heiser LM; Georgii E; Gönen M; Menden MP; Wang NJ; Bansal M; Ammad-ud-din M; Hintsanen P; Khan SA; Mpindi JP; Kallioniemi O; Honkela A; Aittokallio T; Wennerberg K; ; Collins JJ; Gallahan D; Singer D; Saez-Rodriguez J; Kaski S; Gray JW; Stolovitzky G
Nat Biotechnol; 2014 Dec; 32(12):1202-12. PubMed ID: 24880487
[TBL] [Abstract][Full Text] [Related]
15. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
16. Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach.
Huang Y; Sadée W
Drug Discov Today; 2003 Apr; 8(8):356-63. PubMed ID: 12681939
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
18. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
Ali M; Khan SA; Wennerberg K; Aittokallio T
Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.
Tan DS; Gerlinger M; Teh BT; Swanton C
Eur J Cancer; 2010 Aug; 46(12):2166-77. PubMed ID: 20413300
[TBL] [Abstract][Full Text] [Related]
20. A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions.
Mian S; Ball G; Hornbuckle J; Holding F; Carmichael J; Ellis I; Ali S; Li G; McArdle S; Creaser C; Rees R
Proteomics; 2003 Sep; 3(9):1725-37. PubMed ID: 12973733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
